| Name | Title | Contact Details |
|---|
Sweetnight Furniture Co. Ltd. was incorporated in 2008,headquartered in Guangzhou with our manufacturing arm located in "The Furniture City of Asia" in Foshan, China. A specialist in design production of top grade mattresses and bedding sets with care passion. Our mission is to enable people to sleep soundly by creating perfectly healthy bedding sets for our customers. We design, manufacture and sell all kind of mattresses that will surely fit your requirements and budget. Quality is our primary concern. We recently launched our range of organic mattresses to meet the needs of our affluent customers decent needs. Only the best choice materials used. Our organic, environmental friendly and breathable products provide strong support for sleep postures, rest and relaxation to ensure every sleep is a good sleep to prepare you for the next challenging day ahead. Our enthusiastic expert designers, armed with vast experiences in mattress design have combined science, exquisite hand-picked materials and ergonomics with no compromise for health and safety to churn out Sweetnight mattresses. Our products are exported to the USA, UK, Canada, France etc. Over the years, we have undertaken OEM projects in Australia, Belgium etc. We are ranked top in turnovers for mattresses in E- commerce platform for years in Tmall. We invite you to visit our premises to select choice master pieces and indulge in many sweet nights and sweet dreams! 1.Undertake the development of foreign customers and agents,develop and maintain good client relationship. 2.Deal with orders,make and process foreign trade document. 3.Deal with after-service,handle the receiption the clients. 4. Develop an aggressive sales action plan to achieve monthly and annual sales targets for new business targets . 5.Follow up inquiries from B2B or exhibition . 6.Customers follow up and make good service for long-term business .
27North Inc. is a luxury expedition vehicle manufacturer, providing durable and luxurious vehicles tailored to suit adventure seekers, leisurely travelers, and mobile lifestyle enthusiasts. Since 2017, our team has provided our clients with the highest quality, first-class service. With our comprehensive offerings, you can expect to receive superior customer service from the initial contact and beyond.
Progress is achieved by those with the courage to reimagine whats possible. Audi was born more than a century ago with a vision of boldly challenging the status quo and is bound by a promise to imaginatively innovate. We believe the best ideas—the ideas that will define our future—will come from new ways of thinking. We believe everyone should have a voice. We believe in equality. We believe that "we" includes all of us. For these reasons, we strive to create a workplace where diverse ideas are embraced, where people can be themselves, and where everyone comes together to reinvent mobility, drive toward a more sustainable future and create amazing customer experiences.
Bridge Specialty Group, LLC was launched in February 2021 by Brown & Brown, Inc. to encompass its broad portfolio of wholesale insurance businesses and is focused on bringing the power of its collective size and specialty to the wholesale brokerage marketplace. Composed of more than 25 boutique brands, Bridge Specialty Group is creating a more seamless way to connect the varying needs of our retail partners with the market clout and talents of our wholesale entities. To learn more about Bridge Specialty Group and our team of niche-focused brands, visit our website at bridgespecialtygroup.com.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.